D. Ross Camidge
罗斯·卡米奇
MD, PhD, FRCP
Joyce Zeff Chair in Lung Cancer Research; Director, Thoracic Oncology Clinical Program, University of Colorado Anschutz Medical Campus乔伊斯·泽夫肺癌研究讲席教授；科罗拉多大学安舒茨医疗园区胸部肿瘤学临床项目主任
👥Biography 个人简介
D. Ross Camidge, MD, PhD, FRCP holds the Joyce Zeff Chair in Lung Cancer Research and directs the Thoracic Oncology Clinical Program at the University of Colorado Anschutz Medical Campus. He is a preeminent figure in the development of ALK-targeted therapy and molecularly driven lung cancer treatment more broadly. Dr. Camidge conducted key early clinical work with crizotinib in ALK+ NSCLC at Colorado and subsequently served as the principal investigator of the ALTA-1L trial, which established brigatinib as a superior first-line alternative to crizotinib in ALK+ advanced NSCLC with particular superiority in patients with baseline brain metastases. He has been at the forefront of MET exon 14 skipping mutation characterization and MET amplification as both a primary oncogenic driver and a resistance mechanism to EGFR inhibitors, contributing to the clinical development of capmatinib and tepotinib in METex14-altered NSCLC. Dr. Camidge is also known for his work in early drug development, having led multiple phase I trials at Colorado across a range of targeted agents. He is a prolific author and educator, regularly contributing to ASCO, ESMO, and IASLC annual meetings, and has authored or co-authored more than 300 peer-reviewed publications.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
ALTA-1L — Brigatinib vs Crizotinib in First-Line ALK+ NSCLC
Served as principal investigator of the ALTA-1L phase III trial comparing brigatinib to crizotinib as first-line therapy in ALK+ advanced NSCLC, demonstrating superior PFS (24.0 vs 11.0 months), higher intracranial response rates, and improved outcomes in patients with baseline brain metastases, supporting brigatinib as a first-line option.
METex14 Skipping and MET Amplification as Targetable Drivers
Contributed clinical and translational insights to the characterization of MET exon 14 skipping alterations as actionable primary drivers in NSCLC and MET amplification as an acquired resistance mechanism to EGFR inhibitors; participated in capmatinib and tepotinib development trials defining activity in METex14-selected populations.
Early ALK Inhibitor Clinical Development at Colorado
Conducted early clinical studies of crizotinib in ALK+ NSCLC at the University of Colorado, building one of the first academic ALK+ patient cohorts and generating molecular profiling and clinical outcome data that informed dosing strategies and patient selection criteria for larger phase II/III trials.
Early-Phase Drug Development Program
Established and leads a comprehensive early-phase oncology drug development program at Colorado, conducting phase I trials across a spectrum of targeted agents including next-generation ALK, RET, MET, and HER2-directed therapies, and contributing to the scientific rationale for novel combinations in acquired resistance settings.
Representative Works 代表性著作
Brigatinib versus crizotinib in ALK-inhibitor-naïve advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial
Journal of Clinical Oncology (2021)
Final ALTA-1L results confirming significantly superior PFS with brigatinib over crizotinib (24.0 vs 11.0 months) in first-line ALK+ advanced NSCLC with sustained intracranial superiority.
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
New England Journal of Medicine (2010)
Landmark early clinical study of crizotinib in ALK+ NSCLC demonstrating remarkable response rates (57%) in a heavily pretreated population, supporting accelerated approval of crizotinib.
MET exon 14 alterations in non-small cell lung cancer: clinicopathological characteristics and sensitivity to MET inhibitors
Journal of Thoracic Oncology (2021)
Comprehensive review and original data characterizing clinicopathological features of METex14-skipping NSCLC and emerging evidence for selective MET inhibitor efficacy in this population.
Defining resistance to targeted therapies in oncology
Nature Reviews Clinical Oncology (2020)
Conceptual framework paper proposing standardized criteria for classifying primary, acquired, and adaptive resistance to targeted oncology therapies, providing a foundation for consistent trial design and clinical reporting.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 罗斯·卡米奇 的研究动态
Follow D. Ross Camidge's research updates
留下邮箱，当我们发布与 D. Ross Camidge（University of Colorado Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment